Literature DB >> 24635522

Fragment-based inhibitor discovery against β-lactamase.

Derek A Nichols1, Adam R Renslo, Yu Chen.   

Abstract

The production of β-lactamase is one of the primary resistance mechanisms used by Gram-negative bacterial pathogens to counter β-lactam antibiotics, such as penicillins, cephalosporins and carbapenems. There is an urgent need to develop novel β-lactamase inhibitors in response to ever evolving β-lactamases possessing an expanded spectrum of β-lactam hydrolyzing activity. Whereas traditional high-throughput screening has proven ineffective against serine β-lactamases, fragment-based approaches have been successfully employed to identify novel chemical matter, which in turn has revealed much about the specific molecular interactions possible in the active site of serine and metallo β-lactamases. In this review, we summarize recent progress in the field, particularly: the identification of novel inhibitor chemotypes through fragment-based screening; the use of fragment-protein structures to understand key features of binding hot spots and inform the design of improved leads; lessons learned and new prospects for β-lactamase inhibitor development using fragment-based approaches.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24635522      PMCID: PMC4111090          DOI: 10.4155/fmc.14.10

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  109 in total

1.  Experiences in fragment-based drug discovery.

Authors:  Christopher W Murray; Marcel L Verdonk; David C Rees
Journal:  Trends Pharmacol Sci       Date:  2012-03-27       Impact factor: 14.819

Review 2.  Fragment-based approaches in drug discovery and chemical biology.

Authors:  Duncan E Scott; Anthony G Coyne; Sean A Hudson; Chris Abell
Journal:  Biochemistry       Date:  2012-06-14       Impact factor: 3.162

3.  Synthesis and kinetic testing of tetrahydropyrimidine-2-thione and pyrrole derivatives as inhibitors of the metallo-β-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa.

Authors:  Waleed M Hussein; Samar S Fatahala; Zainab M Mohamed; Ross P McGeary; Gerhard Schenk; David L Ollis; Mosaad S Mohamed
Journal:  Chem Biol Drug Des       Date:  2012-07-23       Impact factor: 2.817

4.  Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo.

Authors:  Oliv Eidam; Chiara Romagnoli; Guillaume Dalmasso; Sarah Barelier; Emilia Caselli; Richard Bonnet; Brian K Shoichet; Fabio Prati
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

5.  New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition.

Authors:  Dustin T King; Liam J Worrall; Robert Gruninger; Natalie C J Strynadka
Journal:  J Am Chem Soc       Date:  2012-07-05       Impact factor: 15.419

6.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

7.  Structural insights into the subclass B3 metallo-β-lactamase SMB-1 and the mode of inhibition by the common metallo-β-lactamase inhibitor mercaptoacetate.

Authors:  Jun-Ichi Wachino; Yoshihiro Yamaguchi; Shigetarou Mori; Hiromasa Kurosaki; Yoshichika Arakawa; Keigo Shibayama
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

8.  2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases.

Authors:  Pinhong Chen; Lori B Horton; Rose L Mikulski; Lisheng Deng; Sandeep Sundriyal; Timothy Palzkill; Yongcheng Song
Journal:  Bioorg Med Chem Lett       Date:  2012-08-10       Impact factor: 2.823

9.  Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes.

Authors:  David M Livermore; Shazad Mushtaq; Akihiro Morinaka; Takashi Ida; Kazunori Maebashi; Russell Hope
Journal:  J Antimicrob Chemother       Date:  2012-09-03       Impact factor: 5.790

10.  N-heterocyclic dicarboxylic acids: broad-spectrum inhibitors of metallo-β-lactamases with co-antibacterial effect against antibiotic-resistant bacteria.

Authors:  Lei Feng; Ke-Wu Yang; Li-Sheng Zhou; Jian-Min Xiao; Xia Yang; Le Zhai; Yi-Lin Zhang; Michael W Crowder
Journal:  Bioorg Med Chem Lett       Date:  2012-07-01       Impact factor: 2.823

View more
  3 in total

1.  Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.

Authors:  Juan Carlos Vázquez-Ucha; María Maneiro; Marta Martínez-Guitián; John Buynak; Christopher R Bethel; Robert A Bonomo; Germán Bou; Margarita Poza; Concepción González-Bello; Alejandro Beceiro
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.

Authors:  Magdalena Korczynska; Daniel D Le; Noah Younger; Elisabet Gregori-Puigjané; Anthony Tumber; Tobias Krojer; Srikannathasan Velupillai; Carina Gileadi; Radosław P Nowak; Eriko Iwasa; Samuel B Pollock; Idelisse Ortiz Torres; Udo Oppermann; Brian K Shoichet; Danica Galonić Fujimori
Journal:  J Med Chem       Date:  2015-12-23       Impact factor: 7.446

Review 3.  Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches.

Authors:  Focco van den Akker; Robert A Bonomo
Journal:  Front Microbiol       Date:  2018-04-05       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.